Xingjuan Chao Sells 6,068 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,068 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $145,753.36. Following the sale, the chief executive officer directly owned 781,731 shares of the company’s stock, valued at $18,777,178.62. This represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $23.45 on Thursday. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The stock has a market cap of $900.01 million, a PE ratio of -13.32 and a beta of 0.81. The stock’s fifty day simple moving average is $19.89 and its two-hundred day simple moving average is $19.30. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. As a group, analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

Analyst Upgrades and Downgrades

CBLL has been the topic of several recent analyst reports. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Canaccord Genuity Group increased their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. BTIG Research lifted their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $22.40.

Institutional Trading of CeriBell

Hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its stake in CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after purchasing an additional 854 shares during the last quarter. Sei Investments Co. increased its position in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after buying an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Deutsche Bank AG raised its stake in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares during the period. Finally, Strs Ohio purchased a new position in shares of CeriBell during the 1st quarter valued at $27,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.